Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > BUSINESS
BUSINESS
- Opdivo Secures Top-Selling Title, Veklury Runner Up in July-September: IQVIA
November 25, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- AbbVie Japan Launches Maviret for Age 3 and Older
November 25, 2022
- Takeda’s Dengue Vaccine Bags Fast-Track Tag in US
November 25, 2022
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
- Chugai to Transfer Bonviva Marketing Rights to Taisho
November 25, 2022
- FunPep’s Functional Peptide Fails in Japan PIII Study for Skin Ulcers
November 25, 2022
- Mitsubishi Tanabe, Sumitomo in Antibiotics Collabs with GARDP
November 25, 2022
- Eisai, Shimadzu Kick Off Blood Biomarker Research ahead of Lecanemab Launch
November 24, 2022
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Japan Oncology Market Estimated to Expand 26% by 2030: Fuji Keizai
November 22, 2022
- Nucala Pediatric Form, Berinert SC, Upgraded Diquas Now Available
November 22, 2022
- Kyowa Kirin/MEI Deliver in Japan PII Trial for B-Cell Non-Hodgkin’s Lymphoma
November 21, 2022
- Alnylam’s Amvuttra Hits Japan Market for hATTR Amyloidosis
November 21, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
- RaQualia Gets US$4 Million from Asahi Kasei for Chronic Pain Drug Milestone
November 18, 2022
- Horizon Completes Enrollment of Japan PIII for Thyroid Eye Disease Drug
November 18, 2022
- Yoshindo Bags Japan Sales Rights for Stelara, Pralia Biosimilars from India’s Biocon
November 18, 2022
- Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
- Nichi-Iko Asks for Debt Waiver from Creditors in Turnaround Plan
November 17, 2022
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…